![](/img/cover-not-exists.png)
Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
Collins,, Conlon,, Kannan,, Verma,, Eli,, Lalani,, Crown,Volume:
11
Journal:
Cancers
DOI:
10.3390/cancers11060737
Date:
May, 2019
File:
PDF, 1.37 MB
2019